- JAMES ROGUSKI - APRIL 30, 2023 -
The proposed “Pandemic Treaty” is not about health. It's a business plan to redistribute wealth on a global scale. It offers a financial windfall for Big Pharma. Cui Bono? WHO benefits? The WHO does!
Please watch the video below…
The following excerpts are from the proposed “Zero Draft.”
The (numbers in parentheses) in the list below refer to the legally binding-requirements in the proposed “Pandemic Treaty” that are detailed further below in this article.
Adquira o livro de Heitor De Paola:
"O EIXO DO MAL LATINO AMERICANO E A NOVA ORDEM MUNDIAL"
These excerpts are about money and finance, NOT HEALTH.
The WHO Global Pandemic Supply Chain and Logistics Network (2)
maintaining strategic stockpiles (3)
relevant stakeholders (3)
sources of, manufacturers and suppliers (4)
sustainable production of pandemic-related products (4)
especially active pharmaceutical ingredients (4)
regional purchasing mechanisms (4)
in-kind contributions (4)
existing delivery and distribution options (6)
international consolidation hubs (6)
regional staging areas (6)
a dashboard for pandemic-related product supply capacity and availability (7)
conduct regular tabletop exercises (7)
The Parties COMMIT not to impose regulations that unduly interfere with the trade in, or of, pharmaceutical raw materials and ingredients (8)
unhindered access to pandemic-related products (8)
incentivize manufacturers of pandemic-related products to transfer relevant technology and know-how to capable manufacturer(s) (11)
technology transfer hubs (11)
product development partnerships (11)
intellectual property and trade (12)
mapping manufacturing capacities and demand (12)
licenses to capable manufacturers… to use their intellectual property and other protected substances, products, technology, know-how, information and knowledge used in the process of pandemic response product research, development and production, in particular for pre-pandemic and pandemic-related products (13)
support time-bound waivers of intellectual property rights that can accelerate or scale up manufacturing of pandemic-related products during a pandemic (15)
accelerate the process of approving and licensing pandemic-related products for emergency use (20)
promote and incentivize technology co-creation and joint venture initiatives (25)
distributed manufacturing, licensing, technology transfer and pricing policies (26)
ensuring that these measures do not create any unnecessary administrative hurdles for research (33)
ensuring equitable access to resources (funding or in-kind) (35)
Pathogen Access and Benefit-Sharing System (PABS) System (38)
The PABS System SHALL cover all pathogens with pandemic potential, including their genomic sequences, as well as access to benefits arising therefrom (39)
provide pathogens with pandemic potential from early infections due to pathogens with pandemic potential or subsequent variants to a laboratory recognized or designated as part of an established WHO coordinated laboratory network (40)
upload the genomic sequence of such pathogens with pandemic potential to one or more publicly accessible databases of its choice (41)
Access SHALL be accorded expeditiously by the laboratory recognized or designated as part of an established WHO coordinated laboratory network (42)
Recipients of materials SHALL NOT claim any intellectual property or other rights (43)
Benefit-sharing options available to entities accessing pathogens with pandemic potential (46)
real-time access by WHO to 20% of the production of safe, efficacious and effective pandemic-related products, including diagnostics, vaccines, personal protective equipment and therapeutics (47)
The pandemic-related products SHALL be provided to WHO on the following basis: 10% as a donation and 10% at affordable prices to WHO; (48)
Commitments by the countries where manufacturing facilities are located that they WILL facilitate the shipment to WHO of these pandemic-related products by the manufacturers within their jurisdiction, according to schedules to be agreed between WHO and manufacturers. (48)
Development and operationalization of the PABS System… including through sustaining it in inter-pandemic times (50)
The Parties WILL convene multi-country or regional tabletop exercises every two years (67)
facilitate WHO with rapid access to outbreak areas within the Party’s jurisdiction or control, including through the deployment of rapid response and expert teams, to assess and support the response to emerging outbreaks. (79)
Raise financial resources for effective implementation of the WHO CA+ through bilateral and multilateral funding mechanisms (96)
Domestic funding… not lower than 5% of its current health expenditure to pandemic prevention, preparedness, response and health systems recovery (98)
each Party SHALL: (d) commit to allocate.. XX% of its gross domestic product for international cooperation and assistance on pandemic prevention, preparedness, response and health systems recovery (99)
Provide funding for the development and strengthening of pandemic prevention, preparedness, response and health system recovery programmes of developing country Parties (101)
Facilitate rapid and effective mobilization of adequate financial resources, including from international financing facilities (102)
The Parties represented in relevant regional and international intergovernmental organizations and financial and development institutions SHALL encourage these entities to provide financial assistance for developing country Parties to support them in meeting their obligations under the WHO CA+ (103)
Each Party to the WHO CA+ SHALL have one vote [regardless of how much money they contribute] (105)